About ArQule
ArQule is a company based in Woburn (United States) founded in 1993 was acquired by Merck in December 2019. The company has 39 employees. ArQule has completed 1 acquisition, including Camitro. ArQule operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Woburn, United States
- Employees 39
- Stage Public
- SectorsHealthcare
- Website arqule.com
- Social LinkedIn
- Acquired by Merck (Dec 2019)
- Legal Name Arqule, Inc.
Funding Insights of ArQule
- Total Rounds 2
- Last Round Post-IPO — $9.5M
- First Round $15.7M
(Oct 2017)
- Investors Count 2
All 2 funding rounds of ArQule with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2017 | $9.5M | Post-IPO | – | – | |
| Oct 2017 | $15.7M | Post-IPO | – | – |
3 investors in total: 3 institutional.
Investors in ArQule
ArQule has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, Pontifax Venture Capital and BVF Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pontifax Venture Capital is focused on life sciences investments. | – | pontifax.com | Herzeliya, Israel | |
US private equity investments are managed by BVF Partners. | – | bvflp.com | San Francisco, United States | |
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | merck.com | Kenilworth, United Kingdom |
Investor details for ArQule
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ArQule
11 people are tracked at ArQule (4 in leadership, 7 in board & advisors); the tracked headcount is 39.
| Name | Role | Group |
|---|---|---|
Peter S. Lawrence | President and Chief Operating Officer | Leadership |
Brian Schwartz | Chief Medical Officer | Leadership |
Marc Schegerin | Chief Financial Officer, Head of Strategy and Treasurer | Leadership |
Paolo Pucci | CEO | Leadership |
Patrick J. Zenner | Chairman | Board & advisors |
Timothy C. Barabe | Director | Board & advisors |
Susan L. Kelley | Director | Board & advisors |
Ronald M. Lindsay | Director | Board & advisors |
Michael D. Loberg | Director | Board & advisors |
William G. Messenger | Director | Board & advisors |
Ran Nussbaum | Director | Board & advisors |
Complete people profiles for ArQule
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ArQule
ArQule has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Camitro.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Limited information available | camitro.com | Menlo Park, United States | 2018 | Jan 2001 | $106.2M |
Complete acquisition details for ArQule
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of ArQule
6 dated milestones of ArQule across 26 years, from founding to its latest funding, stage changes and deals.
Competitors of ArQule
ArQule operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of ArQule
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ArQule
Websites that share an audience with ArQule (arqule.com).
Websites whose visitors overlap most with ArQule. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| immunogen.com | 100% | – | – | View details | |
| ariad.com | 100% | – | – | View details | |
healcorp.net | healcorp.net | 100% | – | – | – |
| osip.com | 100% | – | – | View details | |
| onyx-pharm.com | 100% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for ArQule
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Arqule
Complete news archive for ArQule
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ArQule
10 companies that operate in the same segment as ArQule (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ArQule
ArQule was founded in 1993 and raised its 1st funding round 24 years after it was founded.
ArQule is headquartered in Woburn, United States. It is registered at Woburn, Massachusetts, United States.
ArQule has 39 employees.
ArQule is a clinical-stage biotechnology company that develops cancer therapeutics. The company uses its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The companys lead product, tivantinib (ARQ 197), is an orally administered inhibitor of the c-Met receptor tyrosine kinase. Tivantinib is being evaluated as monotherapy and in combination therapy in a Phase 3 trials in microphthalmia transcription factor associated tumors, non-small cell lung cancer, pancreatic adenocarcinoma and hepatocellular carcinoma. The Company has licensed commercial rights to ARQ 197 to Daiichi Sankyo in the United States, Europe, South America and the rest of the world and to Kyowa Hakko Kirin in Japan. The company acquired Cyclis Pharmaceuticals for USD 25M in July 2003.
ArQule's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
ArQule has made 1 acquisition, including Camitro.
ArQule has 3 investors. Key investors include Merck, Pontifax Venture Capital, and BVF Partners.
ArQule operates through Arqule, Inc..
Yes. ArQule was acquired by Merck in December 2019.